The company announced strong durability data at 12 months for patients with low-grade intermediate risk non-muscle invasive bladder cancer treated with UGN-102. 

Deal Snapshot: Pfizer will collaborate with the Flagship Pioneering-backed startup under a broader long-term partnership between the big pharma and venture capital firm.

The Japanese pharma’s new US commercial head Michael Petroutsas talked to Scrip about the launches of Veozah and Izervay.

The company formed around technology from the labs of MIT’s Robert Langer and Giovanni Traverso and already has a lead asset in the clinic.

Arexvy was approved by the US FDA for adults 50-59 with medical conditions that put them at increased risk of severe RSV. Separately, the company ended a cancer deal with SpringWorks.

Rytelo is a first-in-class telomerase inhibitor approved for the treatment of lower-risk myelodysplastic syndromes with transfusion-dependent anemia.